Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan LOARGYS Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    LOARGYS (pegzilarginase-nbln) for Arginase 1 Deficiency

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Part B coverage of provider-administered LOARGYS for hyperargininemia associated with Arginase 1 Deficiency in adults and children age 2 years and older. Coverage includes dosing, administration, monitoring, documentation, and authorization requirements.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyLOARGYS (pegzilarginase-nbln) for Arginase 1 Deficiency
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateMay 14, 2026
    Last ReviewMay 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documenting ARG1-D, age of at least 2 years, specialist involvement, and a dose no greater than 0.2 mg/kg IV once weekly.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥2 yearsMinimum covered age
    0.1 mg/kg weeklyStarting regimen
    0.2 mg/kg weeklyMaximum dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 / 12 monthsAuthorization periods
    40–115 µMNormal arginine range
    AnaphylaxisSafety warning

    Coverage Criteria

    Initial Therapy

    Covered when all of the following are met.

    Initial therapy requirements

    • Diagnosis of hyperargininemia associated with Arginase 1 Deficiency (ARG1-D)
    • Age: Patient is age 2 years or older≥ 2 years
    • Specialist involvement: Prescribed by or in consultation with a metabolic geneticist, neurologist, and/or pediatric specialist
    • Dose: Prescribed IV dose does not exceed 0.2 mg/kg once weekly≤ 0.2 mg/kg IV once weekly
    • Administration: Treatment is physician-administered IV infusion in an office or hospital outpatient department and is not self-administered

    Dosing and Administration

    Dosing and administration must follow FDA labeling or accepted standards of medical practice.

    Administration and dose requirements

    • Starting regimen: Administer 0.1 mg/kg IV once weekly using actual body weight and infuse over 30 minutes0.1 mg/kg IV once weekly
    • Dose adjustment: After four weeks, measure pre-dose plasma arginine 168 hours after the prior dose and adjust toward a pre-dose level near the upper limit of normalTarget near ULN; normal range 40–115 micromolar
    • Administration supervision: Administer every dose under supervision of a health care provider knowledgeable in management of hypersensitivity reactions including anaphylaxis

    Self-administration is not covered. LOARGYS must be administered by a health care provider under appropriate supervision, as a physician-administered IV infusion in an office or hospital outpatient department.

    Initial Therapy

    Initial Therapy Criteria

    Initial therapy is covered for the FDA-approved indication when all ARG1-D eligibility requirements are met.

    Initial LOARGYS therapy

    • Diagnosis: Hyperarginemia associated with Arginase 1 Deficiency (ARG1-D)
    • Age: Patient is at least 2 years old≥ 2 years
    • Specialist involvement: Prescribed by or in consultation with a metabolic geneticist, neurologist, and/or pediatric specialist

    Reauthorization and Continuation

    Reauthorization and Continuation

    Reauthorization is available for 12 months; continued treatment must remain consistent with FDA labeling or accepted standards of medical practice.

    Continuation therapy

    • Qualifying condition: Hyperarginemia associated with Arginase 1 Deficiency
    • Administration: All doses remain under the supervision of a health care provider
    • Authorization period: Reauthorization period is 12 months12 months

    Coding and Monitoring Requirements

    LOARGYS NDCsNDCCovered
    81583-102-01LOARGYS 2 mg, 10-digit NDC
    81583-105-01LOARGYS 5 mg, 10-digit NDC
    81583-0102-01LOARGYS 2 mg, 11-digit NDC
    81583-0105-01LOARGYS 5 mg, 11-digit NDC
    HCPCS CodesHCPCSCovered
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals
    CPT Procedural CodesCPTCovered
    96365Ther/proph/diagn IV infusion, initial
    96372Ther/proph/diagn injection, SC/IM
    Normal plasma arginine range
    Normal range40 to 115 micromolar
    UseReference range for LOARGYS dose adjustment
    Dose-adjustment targetAim for a pre-dose plasma arginine level near the upper limit of normal
    Pre-dose plasma arginine monitoring
    TimingAfter four weeks of administration
    MeasurementMeasure pre-dose plasma arginine
    Collection interval

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Part B Prior Authorization Required

    Prior authorization is required for physician-administered LOARGYS under Part B when billed as an unclassified biologic or drug/biological.

    • Bill the drug under HCPCS J3590 (unclassified biologics) or C9399 (unclassified drugs or biologicals).
    • Administration may be reported with CPT 96365 for initial IV infusion or 96372 for subcutaneous/intramuscular injection.
    Documentation Required

    Required Clinical and Administration Documentation

    Submit clinical and administration documentation supporting the request, including the confirmed diagnosis, patient age, qualified prescriber involvement, and the planned method and setting of administration.

    • Document hyperargininemia associated with Arginase 1 Deficiency (ARG1-D).

    Policy Background

    LOARGYS (pegzilarginase-nbln) is an arginine-specific enzyme indicated for hyperarginemia in adult and pediatric patients age 2 years and older with Arginase 1 Deficiency (ARG1-D). Treatment is used in conjunction with dietary protein restriction.

    Definitions

    ARG1-D
    TermARG1-D
    DefinitionArginase 1 Deficiency is an inherited disorder associated with hyperarginemia
    LOARGYS indicationTreatment of hyperarginemia in patients with Arginase 1 Deficiency, in conjunction with dietary protein restriction
    Arginine-specific enzyme
    ProductLOARGYS (pegzilarginase-nbln)
    Enzyme typeArginine-specific enzyme
    IndicationUsed to treat hyperarginemia associated with Arginase 1 Deficiency

    Dose and Quantity Limits

    LOARGYS quantity limit
    Maximum dose0.2 mg/kg
    FrequencyOnce weekly
    RouteIntravenous (IV)

    Permitted Administration Settings

    Billing Rule

    Meet office infusion and emergency-support requirements

    Provide physician-administered LOARGYS by IV infusion in an office setting. Initiate treatment in a health care setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment.

    • Maintain provider supervision throughout administration.
    • Ensure emergency support is available for hypersensitivity reactions, including anaphylaxis.
    Billing Rule

    Use a monitored hospital outpatient setting

    Physician-administered LOARGYS by IV infusion is permitted in a hospital outpatient department. The site must provide required medical monitoring and emergency support, including access to cardiopulmonary resuscitation equipment.

    • Administer under the supervision of a knowledgeable health care provider.
    Policy Summary
    PayerGold Coast Health Plan
    PolicyLOARGYS (pegzilarginase-nbln) for Arginase 1 Deficiency
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateMay 14, 2026
    Last ReviewMay 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documenting ARG1-D, age of at least 2 years, specialist involvement, and a dose no greater than 0.2 mg/kg IV once weekly.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyReauthorization and ContinuationCoding and Monitoring RequirementsAuthorization, Documentation, and Denial RisksPolicy BackgroundDefinitionsDose and Quantity LimitsPermitted Administration Settings
    Dose:
    IV dose does not exceed 0.2 mg/kg once weekly
    ≤ 0.2 mg/kg IV once weekly
  1. Administration setting: Physician-administered IV infusion in an office or hospital outpatient department
  2. 168 hours after the prior dose
  3. Document that the patient is at least 2 years old.
  4. Identify a prescriber who is, or has consulted with, a metabolic geneticist, neurologist, and/or pediatric specialist.
  5. Document physician-administered IV infusion in an office or hospital outpatient department (HOPD), or the applicable supervised subcutaneous administration details.
  6. Documentation Required

    Dose and Safety Monitoring Documentation

    Document dosing, plasma arginine monitoring, administration, and safety precautions. LOARGYS must be initiated in a health care setting with appropriate monitoring and support for hypersensitivity reactions, including anaphylaxis.

    • Standard dosing is 0.1 mg/kg IV once weekly using actual body weight; the covered dose must not exceed 0.2 mg/kg IV once weekly.
    • Infuse IV doses over 30 minutes. After four weeks, measure pre-dose plasma arginine 168 hours after the prior dose and document dose-adjustment rationale; target the normal range of 40–115 micromolar, with pre-dose levels near the upper limit of normal.
    • After eight weeks of once-weekly IV therapy, subcutaneous LOARGYS may be used at the same dosage when appropriate.
    • Document administration under supervision of a knowledgeable health care provider, with appropriate medical monitoring, support measures, and access to cardiopulmonary resuscitation equipment.
    Denial Risk

    Failure to Meet ARG1-D Criteria

    Coverage may be denied when the request does not satisfy all ARG1-D criteria or when dosing is outside FDA labeling or accepted standards of medical practice.

    • The patient must have hyperargininemia associated with ARG1-D.
    • The patient must be at least 2 years old.
    • The drug must be prescribed by, or used in consultation with, a metabolic geneticist, neurologist, and/or pediatric specialist.
    • The requested dose must not exceed 0.2 mg/kg IV once weekly.
    • Requests that do not support the approved indication, eligibility requirements, or an appropriately documented dose may be denied.
    Denial Risk

    Self-Administration Not Allowed

    LOARGYS is not covered for self-administration. All IV or subcutaneous doses must be administered under the supervision of a health care provider knowledgeable in managing hypersensitivity reactions, including anaphylaxis.

    • For IV therapy, administration is physician-administered in an office or HOPD.
    • Do not request or bill coverage when the patient administers LOARGYS independently without required health care provider supervision.
  7. Use appropriate monitoring and support measures for hypersensitivity reactions, including anaphylaxis.